Weekly Recap: FDA seeks data on CMPS NDA and COMP360 52—week results

COMPASS Pathways Plc Sponsored ADR (NASDAQ:CMPS) said its rolling NDA for COMP360 faces FDA requests for more information and an uncertain 60—day acceptance timeline, even as Part C data show repeat doses delivered rapid, durable responses through 52 weeks and the company outlines CPT/J—code reimbu…